United States · FDA National Drug Code directory
GARDASIL 9
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0006-4119_318ae380-736e-4519-b865-2f6b443d36ba
- Product NDC
- 0006-4119
- Form
- INJECTION, SUSPENSION
- Composition / generic term
- Human Papillomavirus 9-valent Vaccine, Recombinant
- Labeler
- Merck Sharp & Dohme LLC
- Marketing category
- BLA
- Marketing start / end (source format)
- 20141210
- Source listing expiry
- 20271231
Source-listed ingredients
- HUMAN PAPILLOMAVIRUS TYPE 6 L1 CAPSID PROTEIN ANTIGEN — 30 ug/.5mL
- HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN — 40 ug/.5mL
- HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN — 60 ug/.5mL
- HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN — 40 ug/.5mL
- HUMAN PAPILLOMAVIRUS TYPE 31 L1 CAPSID PROTEIN ANTIGEN — 20 ug/.5mL
- HUMAN PAPILLOMAVIRUS TYPE 33 L1 CAPSID PROTEIN ANTIGEN — 20 ug/.5mL
- HUMAN PAPILLOMAVIRUS TYPE 45 L1 CAPSID PROTEIN ANTIGEN — 20 ug/.5mL
- HUMAN PAPILLOMAVIRUS TYPE 52 L1 CAPSID PROTEIN ANTIGEN — 20 ug/.5mL
- HUMAN PAPILLOMAVIRUS TYPE 58 L1 CAPSID PROTEIN ANTIGEN — 20 ug/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 10 VIAL, SINGLE-DOSE in 1 CARTON (0006-4119-03) / .5 mL in 1 VIAL, SINGLE-DOSE (0006-4119-01) · 0006-4119-03
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →